Table 1.
Results of MR analyses between liability to thyroid function and circulating AMH levels.
| Exposure | N SNPs | Inverse variance weighted | MR Egger | Weighted median | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Beta | CI | pval | Beta | CI | pval | Beta | CI | pval | |||||
| Normal range TSH, ThyroidOmics | 54 | -0.022 | -0.091- 0.047 | 0.531 | -0.145 | -0.312- 0.023 | 0.097 | -0.031 | -0.136- 0.074 | 0.562 | |||
| AITD | 15 | -0.096 | -0.223- 0.031 | 0.139 | -0.232 | -0.606- 0.143 | 0.247 | -0.139 | -0.315- 0.037 | 0.122 | |||
| no-AITD | 39 | 0.006 | -0.075- 0.086 | 0.889 | -0.117 | -0.306- 0.071 | 0.229 | -0.022 | -0.147- 0.102 | 0.724 | |||
| Normal range fT4, ThyroidOmics | 23 | -0.073 | -0.168- 0.022 | 0.130 | -0.061 | -0.270- 0.148 | 0.574 | -0.041 | -0.182- 0.100 | 0.567 | |||
| DIO1+DIO2 | 5 | -0.018 | -0.172- 0.136 | 0.819 | -0.046 | -0.394- 0.301 | 0.810 | -0.013 | -0.179- 0.152 | 0.873 | |||
| no-DIO1+DIO2 | 18 | -0.106 | -0.226- 0.014 | 0.082 | -0.130 | -0.424- 0.163 | 0.396 | -0.131 | -0.307- 0.046 | 0.146 | |||
| Subclinical hypothyroidism, ThyroidOmics | 7 | -0.023 | -0.084- 0.039 | 0.471 | -0.089 | -0.350- 0.172 | 0.534 | -0.030 | -0.106- 0.046 | 0.439 | |||
| Subclinical hyperthyroidism, ThyroidOmics | 7 | 0.001 | -0.046- 0.048 | 0.972 | 0.096 | -0.129- 0.321 | 0.441 | 0.010 | -0.052- 0.072 | 0.760 | |||
| Overt hypothyroidism, 23andMe | 13 | -0.020 | -0.080- 0.041 | 0.521 | -0.063 | -0.203- 0.078 | 0.401 | -0.040 | -0.124- 0.043 | 0.345 | |||
AMH, anti-Müllerian hormone; TSH, thyroid stimulating hormone; fT4, thyroxine (free tetraiodothyronine); GWAS, genome-wide association study.